Human α-Defensin-5 Efficiently Neutralizes Clostridioides difficile Toxins TcdA, TcdB, and CDT
暂无分享,去创建一个
[1] R. Benz,et al. Human peptide α‐defensin‐1 interferes with Clostridioides difficile toxins TcdA, TcdB, and CDT , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[2] David M. Anderson,et al. Structural elucidation of the Clostridioides difficile transferase toxin reveals a single-site binding mode for the enzyme , 2020, Proceedings of the National Academy of Sciences.
[3] A. Grishaev,et al. Structure of the cell-binding component of the Clostridium difficile binary toxin reveals a di-heptamer macromolecular assembly , 2020, Proceedings of the National Academy of Sciences.
[4] S. Fischer,et al. Human alpha-defensin-1 protects cells from intoxication with Clostridium perfringens iota toxin , 2018, Pathogens and disease.
[5] K. Aktories,et al. Cellular Uptake and Mode-of-Action of Clostridium difficile Toxins. , 2018, Advances in experimental medicine and biology.
[6] S. Hopkins,et al. Impact of recurrent Clostridium difficile infection: hospitalization and patient quality of life , 2017, The Journal of antimicrobial chemotherapy.
[7] Kevin W. Eliceiri,et al. ImageJ2: ImageJ for the next generation of scientific image data , 2017, BMC Bioinformatics.
[8] M. A. Farrow,et al. Clostridium difficile Toxins TcdA and TcdB Cause Colonic Tissue Damage by Distinct Mechanisms , 2016, Infection and Immunity.
[9] S. Clare,et al. Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections , 2015, mBio.
[10] M. Jit,et al. Excess length of stay and mortality due to Clostridium difficile infection: a multi-state modelling approach. , 2014, The Journal of hospital infection.
[11] H. Goudarzi,et al. Clostridium difficile Infection: Epidemiology, Pathogenesis, Risk Factors, and Therapeutic Options , 2014, Scientifica.
[12] M. P. Bauer,et al. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[13] N. Minton,et al. University of Birmingham Importance of Toxin A, Toxin B, and CDT in virulence of an epidemic Clostridium difficile strain , 2013 .
[14] S. Tart. The Role of Vancomycin and Metronidazole for the Treatment of Clostridium difficile–Associated Diarrhea , 2013, Journal of pharmacy practice.
[15] Kevin W Eliceiri,et al. NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.
[16] J. Rood,et al. The role of toxin A and toxin B in the virulence of Clostridium difficile. , 2012, Trends in microbiology.
[17] K. Aktories. Bacterial protein toxins that modify host regulatory GTPases , 2011, Nature Reviews Microbiology.
[18] K. Aktories,et al. Cholesterol- and Sphingolipid-rich Microdomains Are Essential for Microtubule-based Membrane Protrusions Induced by Clostridium difficile Transferase (CDT)* , 2011, The Journal of Biological Chemistry.
[19] Pamela Sears,et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. , 2011, The New England journal of medicine.
[20] Nigel P. Minton,et al. The role of toxin A and toxin B in Clostridium difficile infection , 2010, Nature.
[21] Constantinos Zamboglou,et al. Clostridial Glucosylating Toxins Enter Cells via Clathrin-Mediated Endocytosis , 2010, PloS one.
[22] J. Wehland,et al. Clostridium difficile Toxin CDT Induces Formation of Microtubule-Based Protrusions and Increases Adherence of Bacteria , 2009, PLoS pathogens.
[23] A. Waring,et al. Human α-Defensins Inhibit Hemolysis Mediated by Cholesterol-Dependent Cytolysins , 2009, Infection and Immunity.
[24] J. Mossong,et al. Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[25] K. Aktories,et al. Human alpha-defensins inhibit Clostridium difficile toxin B. , 2008, Gastroenterology.
[26] K. Aktories,et al. Structure and mode of action of clostridial glucosylating toxins: the ABCD model. , 2008, Trends in microbiology.
[27] Klaus Aktories,et al. Auto-catalytic Cleavage of Clostridium difficile Toxins A and B Depends on Cysteine Protease Activity* , 2007, Journal of Biological Chemistry.
[28] S. Kaufmann,et al. Human alpha-defensins neutralize toxins of the mono-ADP-ribosyltransferase family. , 2006, The Biochemical journal.
[29] I. Just,et al. Cellular stability of Rho‐GTPases glucosylated by Clostridium difficile toxin B , 2006, FEBS letters.
[30] E. Kuijper,et al. Emergence of Clostridium difficile-associated disease in North America and Europe. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[31] L. Valiquette,et al. Mortality attributable to nosocomial Clostridium difficile–associated disease during an epidemic caused by a hypervirulent strain in Quebec , 2005, Canadian Medical Association Journal.
[32] S. Kaufmann,et al. Human alpha-defensins neutralize anthrax lethal toxin and protect against its fatal consequences. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[33] Louis Valiquette,et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity , 2004, Canadian Medical Association Journal.
[34] M. Sauerborn,et al. Comparative sequence analysis of theClostridium difficile toxins A and B , 1992, Molecular and General Genetics MGG.
[35] R. Benz,et al. Mechanism of C2-toxin inhibition by fluphenazine and related compounds: investigation of their binding kinetics to the C2II-channel using the current noise analysis. , 2003, Journal of molecular biology.
[36] T. Ganz,et al. Paneth cell trypsin is the processing enzyme for human defensin-5 , 2002, Nature Immunology.
[37] K. Aktories,et al. Characterization of the Enzymatic Component of the ADP-Ribosyltransferase Toxin CDTa from Clostridium difficile , 2001, Infection and Immunity.
[38] R. Benz,et al. Interaction of Clostridium botulinum C2‐toxin with lipid bilayer membranes and vero cells: inhibition of channel function by chloroquine and related compounds in vitro and intoxification in vivo , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[39] F. Gisou van der Goot,et al. The bacterial toxin toolkit , 2001, Nature Reviews Molecular Cell Biology.
[40] R. Spencer. Clinical impact and associated costs of Clostridium difficile-associated disease. , 1998, The Journal of antimicrobial chemotherapy.
[41] G. Corthier,et al. Production of a complete binary toxin (actin-specific ADP-ribosyltransferase) by Clostridium difficile CD196 , 1997, Infection and immunity.
[42] K. Aktories,et al. Inactivation of Ras by Clostridium sordellii Lethal Toxin-catalyzed Glucosylation (*) , 1996, The Journal of Biological Chemistry.
[43] M. Mann,et al. Glucosylation of Rho proteins by Clostridium difficile toxin B , 1995, Nature.
[44] M. Selsted,et al. Defensins in granules of phagocytic and non-phagocytic cells. , 1995, Trends in cell biology.
[45] K. Aktories,et al. The low molecular mass GTP-binding protein Rho is affected by toxin A from Clostridium difficile. , 1995, The Journal of clinical investigation.
[46] R. Benz,et al. Interaction of Clostridium botulinum C2 toxin with lipid bilayer membranes. Formation of cation-selective channels and inhibition of channel function by chloroquine. , 1994, The Journal of biological chemistry.
[47] T. Ganz,et al. Defensins: a family of antimicrobial and cytotoxic peptides. , 1994, Toxicology.
[48] R I Lehrer,et al. Defensins: antimicrobial and cytotoxic peptides of mammalian cells. , 1993, Annual review of immunology.
[49] T. Ganz,et al. Defensins , 1990, European journal of haematology.
[50] M. Selsted,et al. Determination of the disulfide array in the human defensin HNP-2. A covalently cyclized peptide. , 1989, The Journal of biological chemistry.